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Abstract 
Background 
Adeno-associated vectors (rAAV) have been used to attain long-term liver gene expression. 
In humans, the cellular immune response poses a serious obstacle for transgene persistence 
while neutralizing humoral immunity curtails re-administration. Porphobilinogen deaminase 
(PBGD) haploinsufficiency (acute intermittent porphyria) benefits from liver gene transfer in 
mouse models and clinical trials are about to begin. In this work, we sought to study in non-
human primates the feasibility of repeated gene-transfer with intravenous administration of 
rAAV5 vectors under the effects of an intensive immunosuppressive regimen and to analyze 
its ability to circumvent T-cell immunity and thereby prolong transgene expression. 
Methods 
Three female Macaca fascicularis were intravenously injected with 1x10
13
 genome copies/kg 
of rAAV5 encoding the human PBGD. Mycophenolate mofetil (MMF), anti-thymocyte 
immunoglobulin, methylprednisolone, tacrolimus and rituximab were given in combination 
during 12 weeks to block T- and B-cell mediated adaptive immune responses in two 
macaques. Immunodeficient and immunocompetent mice were intravenously injected with 
5x10
12
 genome copies/kg of rAAV5-encoding luciferase protein. Forty days later MMF, 
tacrolimus and rituximab were daily administrated to ascertain whether the 
immunosuppressants or their metabolites could interfere with transgene expression. 
Results 
Macaques given a rAAV5 vector encoding human PBGD developed cellular and humoral 
immunity against viral capsids but not towards the transgene. Anti-AAV humoral responses 
were attenuated during 12 weeks but intensely rebounded following cessation of the 
immunosuppressants. Accordingly, subsequent gene transfer with a rAAV5 vector encoding 
green fluorescent protein was impossible. One macaque showed enhanced PBGD expression 
25 weeks after rAAV5-pbgd administration but overexpression had not been detected while 
the animal was under immunosuppression. As a potential explanation, MMF decreases 
transgene expression in mouse livers that had been successfully transduced by a rAAV5 
several weeks before MMF onset. Such a silencing effect was independent of AAV 
complementary strand synthesis and requires an adaptive immune system. 
Conclusions 
These results indicate that our transient and intensive pharmacological immunosuppression 
fails to improve AAV5-based liver gene transfer in non-human primates. The reasons include 
an incomplete restraint of humoral immune responses to viral capsids that interfere with 
repeated gene transfer in addition to an intriguing MMF-dependent drug-mediated 
interference with liver transgene expression. 
Keywords 
Adeno-associated virus serotype 5, Neutralizing antibodies, Re-administration, Vector 
Immunology/Host Responses, Immunomodulation 
Background 
Acute intermittent porphyria (AIP) is an autosomal dominant inherited disease clinically 
characterized by life-threatening acute neurologic attacks and is biochemically defined by 
partial deficiency of porphobilinogen deaminase (PBGD) activity in the liver. Recombinant 
adeno-associated viral (rAAV) vectors are a promising gene therapy tool for the correction of 
genetic disorders [1–4]. Recently, we and others [5,6] have reported sustained hepatic 
expression of human PBGD in the liver of a mouse model of AIP transduced with rAAV-
pbgd vectors. A multi-center national phase I/II clinical trial with rAAV vector serotype 5 
will be executed as a prophylactic treatment for patients with a severe status of AIP. 
The genome of the rAAV vector persists predominantly in episomal forms, thereby 
increasing safety by reducing the risk of insertional mutagenesis. However, this feature may 
favour loss of genomes and transgene expression over time due to hepatocyte turn-over. 
Although the hepatocyte proliferation rate is normally very low in adult mammals, sustained 
transgene expression throughout the life of the patient will require repetitive administration. 
However, rAAV-mediated liver gene transduction may be compromised by preexisting 
immunity to AAV. First, neutralizing antibodies (nABs) at the time of administration directly 
hamper the clinical DNA delivery system [7]. Secondly, prior infection of the patients with 
natural or recombinant AAVs leads to formation of memory CD8+ T cells which readily 
undergo activation upon re-exposure to the AAV capsids [8,9]. 
Delivery of viral vectors under transient pharmacological immunosuppression is a 
conceivable strategy to diminish host immune responses against vector capsid proteins and 
may provide a strategy to permit repeated rAAV vector administrations [10–13]. However, 
laboratory mice did not reproduce T cell–mediated destruction of rAAV-transduced 
hepatocytes [14]. As a consequence, experiments in primates are clearly necessary to guide 
clinical development because mouse experiments are not considered predictive from the point 
of view of immunogenicity. 
Recently, we have demonstrated in non-human primates that the adaptive immune response 
to a first generation adenoviral vector could be averted by a course of immunosuppression 
which combines B-cell depletion and T-cell inhibition with clinically available drugs [15]. 
Such a regimen permitted up to four re-administration cycles. The aim of this study was to 
investigate in non-human primates the feasibility of gene re-transfer with intravenous 
administration of rAAV5 vectors under the effects of the same intensive immunosuppressive 
(IS) regimen used with the first generation adenoviral vector. 
Results from the hemophilia trials [8,9] that involved serotype 2-based rAAV vectors have 
demonstrated that the activation of capsid-specific cytotoxic CD8+ T cells extinguishes 
transgene expression in a matter of weeks. In a more recent clinical trial using serotype 8 
self-complementary rAAV vector, factor IX transgene expression was preserved in two 
patients when a short course of glucocorticoid therapy was given [16]. Thus, the second aim 
of this study was to investigate the ability of transient IS regimes to circumvent T-cell 
immunity and thereby prolong transgene expression. 
Methods 
Construction of plasmids and production of rAAV5 
The expression cassette encodes the human cDNA of the housekeeping PBGD isoform or the 
reporter genes (luciferase or enhanced green fluorescence protein, eGFP) flanked by the 
inverted terminal repeats from AAV2. Transgenes are under the control of the liver specific 
human α-1-antitrypsin promoter with regulatory sequences from the human albumin enhancer 
(EalbAAT promoter) and include the human PBGD polyadenylation sequence [5] (bases 
9550–9655 GenBank Accession No. M95623). The rAAV5 vectors were generated in Sf9 
insect cells [17]. Vector particles were purified and final concentration of different batches 
was determined by quantitative polymerase chain reaction (QPCR), as previously described 
[5]. 
Macaque experiments and immunosuppression treatment 
Three female captive bred NHP (Macaca fascicularis, 4 to 5-years of age) were intravenously 
injected with 1x10
13
 gc/kg rAAV5-pbgd following the schematic time line presented in 
Figure 1A. A second vector infusion of 3x10
12
 gc/kg rAAV5-eGFP was performed in these 
three macaques and an additional control naïve macaque. Liver biopsies were obtained one 
week before and 2 and 4 weeks after the rAAV5-pbgd injection. Vector copy number and 
PBGD activity were assessed from a mix of 4 liver samples corresponding to each animal at 
each time point. 
Figure 1 An immunosuppressive pharmacological regimen delays and weakens 
immunity against rAAV5 capsid antigens. A) Schematic timeline representation of the 
administration of two rAAV serotype 5 vectors in macaques under combined 
pharmacological immunosuppression. rAAV5-pbgd was injected first and rAAV5-egfp 
second. Animals are colour coded, identified by the NHP-digit code and their timeline 
represented by a horizontal arrow. B) Sequential follow-up of serum rAAV5 neutralizing 
antibodies in the serum of the colour-coded animals. C) In vitro mitogenic response of 
peripheral blood mononuclear cells (PBMC) at the indicated time points to rAAV5 capsids, 
measured by 
3 H-Thy incorporation. D) Sequential follow-up of proviral rAAV5-pbgd DNA 
detection from serum samples of the colour-coded animals by quantitative PCR of vector 
DNA. Each dot represents the average of two independent measurements for each sample at a 
time point 
Macaques were sacrificed twenty five weeks after rAAV5-pbgd i.v. injection, corresponding 
to two weeks after the administration of rAAV5-egfp. The control naïve macaque injected 
with rAAV5-egfp was sacrificed two weeks after vector injection. 
The B and T-cell IS regimen was administered as described: (i) B-cell-depleting Rituximab 
(20 mg/kg/dose i.v., Mabthera, ROCHE, Switzerland) at days −9, -6, -3, immediately before 
rAAV injections and weekly after the viral administration, (ii) two i.v. doses of 3 mg/kg of T-
cell-depleting anti-thymocyte gamma-globulin (ATG) (Genzyme Polyclonals, SAS, France) 
at days −2 and −1 before rAAV injection. (iii) Methylprednisolone (Solu-moderin, Pfizer SA, 
Spain) applied intramuscularly 10 min before the ATG infusion at a dose of 100 mg on day 
−2 and 50 mg on day −1. (iv) Mycophenolate mofetil (MMF) (CellCept, Roche Pharma AG, 
Demark) at a dose of 25–30 mg/kg/day and (v) 0.25 mg /kg/day of tacrolimus 
(FK506)(Astellas Pharma, Madrid, Spain). MMF and FK506 were given orally from day −2 
daily to the end of IS protocol (shaded areas). This protocol maintained serum levels within 
the range of 2 to 4 μg/mL for mycophenolic acid (the active metabolite of MMF) and 2 to 8 
ng/mL for tacrolimus, as measured in a different cohort of Macaca fascicularis. Toxicities for 
all of these agents are well-described in non-human primates. 
All animal experiments were approved by the ethics committee of the University of Navarra 
in accordance with Spanish regulations (study approval CEEA038-09). Experiments in 
primates are clearly necessary to guide clinical development because mouse experiments are 
not considered predictive from the point of view of immunogenicity. However, ethical and 
regulatory constraints limit the number of NHP available for this experimentation to a 
minimum. 
Mouse experiments 
The effect of IS drugs on transgene expression was monitored in eight female BALB/c mice 
intravenously injected with a dose of rAAV5-luciferase (5x10
12
 gc/kg). At day forty, five 
animals received daily intraperitoneal administration of 30 mg MMF /kg/day during the first 
week and a combination of MMF, FK506 (0,25 mg/kg/day) and Rituximab (20 mg/kg/day) 
during the second week. Eighteen BALB/c and nineteen Rag
−/−
 female mice were injected, 
i.v., with 5x10
12
 gc/kg of rAAV5-luciferase. Rag
−/−
 mice have small lymphoid organs and do 
not contain mature B and T lymphocytes as Rag
−/−
 is needed for the V(D)J recombination of 
immunoglobulin and T cell receptor genes. Four weeks after vector injection animals were 
injected i.p. with a dose of 30 mg of MMF/kg/day for two weeks. Non-invasive luciferase 
expression measurements were performed in living mice, as previously described [18]. 
Transgene expression 
Human PBGD transgene expression was measured by enzymatic activity and 
immunohistochemistry, as previously reported for PBGD [5], or real-time QPCR analysis. 
Total RNA was purified from homogenized tissue samples using TRIzol® reagent 
(Invitrogen, Carlsbad, CA). Reverse transcriptions with random primers were performed at 
37 °C for 50 min using M-MLV Reverse transcriptase (Invitrogen). Real-time QPCR was 
performed using primers designed to amplify a 51 base pair fragment of the human 
recombinant 3´UTR-poly A pbgd region (pAPBGDfw5´-GCTAGCCTTTGAATGTAACCA-
3´, pAPBGDrv5´-CCTTCAGAACTGGTTTATTAGTAGG-3´), or a 43 base pair region of 
the eGFP sequence (eGFPfw, 5'–GTCCGCCCTGAGCAAAGA–3'; eGFPrv, 5'–
TCCAGCAGGACCATGTGATC–3').. Endogenous mouse β-actin sequence (mBactinfw, 5'–
CGCGTCCACCCGCGAG–3'; mBactinrv, 5'–CCTGGTGCCTAGGGCG–3'; product length: 
193 bp) or endogenous simian β-actin (sBactinfw, 5'–
GAGCGGGAAATCGTGCGTGACATT–3'; sBactinrv, 5'–
GAAGGTAGTTTCGTGGATGCC–3'; product length: 210 bp) were also amplified to 
equalize quantity. QPCR was performed in an iQ5 real-time PCR detection system (Bio-Rad, 
Hercules, CA) using iQ SYBR green supermix. PCR amplification conditions were as 
follows: 95 °C for 5 min, 40 cycles of 95 °C for 15 sec, 60 °C for 15 sec, 72 °C for 25 s and 
80 °C for 10 s; and a final extension for 10 min at 72 °C). A melting curve was generated by 
raising the incubation temperature from 65 °C to 95 °C to confirm amplification specificity. 
The amount of each transcript was expressed according to the formula 2
Ct(GAPDH)-Ct(gene)
, 
where Ct is the cycle at which the fluorescence rises appreciably above background 
fluorescence. 
Proviral DNA quantification in liver samples and serum vector detection 
Detection of the specific rAAV5-pbgd or rAAV5-luciferase plasmid sequences was 
performed in genomic DNA of harvested samples isolated using the QIAmp Blood&Tissue 
DNA Mini-kit (Qiagen). Genomic DNA was subjected to QPCR using specific primers as 
described above for transgene expression. For normalization of amount of genomic DNA, 
specific primers for murine and simian gapdh sequence were used (mGAPDHfw, 5'–
CCAAGGTCATCCATGACAAC–3'; mGAPDHrv, 5'–TGTCATACCAGGAAATGAGC–3'; 
sGAPDHfw 5'–GTCAGTGGTGGACCTGACCT–3'; sGAPDHrv, 5'–
TGCTGTAGCCAAATTCGTTG–3'). 
Measurement of humoral and cellular anti-AAV5 responses 
Sera were obtained by tail vein puncture and stored at −80 °C. Neutralizing antibody assays 
to rAAV5-luciferase were performed with serial dilutions of serum that were mixed with 
1x10
9
 genome copies of rAAV5-luciferase. The mix was incubated at 37 °C for 1 h and then 
the mixture was added to PLC-PRF5 cells (1x10
4
 cells per well) in a 96-well plate. Cells 
were harvested 144 h later and assayed for luciferase activity (D-luciferin Luciferase kit, 
Promega) using the Living Image 2.20 software package (Xenogen). Sera were scored as 
positive for neutralizing anti-rAAV5 antibodies if the light intensity was less than 50 % of 
that observed when rAAV5 was pre-incubated with negative control sera. Data are reported 
using a curve adjusted to extrapolate the serum dilution for 50 % inhibition of rAA5-
luciferase transduction (IC50). 
Antibodies directed to viral capsids were titrated by ELISA. Microtiter wells were coated by 
overnight incubation at 4 °C with purified viral capsids (1 μg/ml) in 0.1 M sodium carbonate 
buffer. After washing and blocking the wells with Phosphate Buffer Saline and 10 % bovine 
serum albumin, sera were tested at serial dilutions. Following extensive washing specific 
binding of Goat anti-monkey IgG, IgM, IgA biotin conjugated (1/10.000 dilution, SAB 1062, 
Open Biosystem) was developed with streptavidin-avidin peroxidase at 1/250 and TBM 
substrate (BD biosciences). Antibody titers correspond to the highest serum dilution to yield 
three times the absorbance of a negative serum and were expressed as the reciprocal value of 
the dilution. 
To evaluate the cellular immune response induced against the vector, monkey leukocytes 
were purified from peripheral blood by centrifugation through Ficoll-Hypaque (GE 
Healthcare, Piscataway, NJ) and counted in a Z2 Coulter Counter (Beckman Coulter). In vitro 
mitogenic responses to AAV capsids was measured by [methyl-3 H] Thymidine 
incorporation of isolated leukocytes (5x10
5
 cells/mL) cultured for 72 h in medium alone [X-
vivo medium (BioWhittaker) supplemented with 2 mM glutamax (Invitrogen), and 1 % 
penicillin/streptomycin (Invitrogen)] or containing serial dilutions of rAAV5 vector from 10–
0.01 μg prot./mL. To assess the ability of cells to respond to mitogens, a mix of the phorbol 
ester 12-myristate- 13-acetate (0.01 μg/mL) and Ionomicine (1 μg/mL) was used in each 
experiment (Sigma-Aldrich, St. Louis, MO) as a positive control. [3 H]-thymidine uptake was 
assessed by filtration on an automatic cell harvester and by measuring nuclear radioactivity 
(filters) on a scintillation plate reader (Topcount). The stimulation Index (S.I.) was defined as 
the mean counts per minute (cpm) of the response of the antigen-stimulated cells divided by 
the mean cpm of the of cell cultures without antigen. 
Humoral anti-human PBGD protein detection 
The samples were analyzed for antibodies to human PBGD protein by Western blotting. 
Purified recombinant human PBGD protein was resolved by electrophoresis by 12 % SDS-
PAGE and transferred onto a PVDF membrane (Amersham Hybond-PTM, Bucks, UK). After 
blocking, the membranes were incubated with a rabbit polyclonal anti-PBGD (1:300 H-300, 
Santa Cruz, CA) as a positive control, or sera from macaques NHP001, NHP002 or NHP003 
(diluted 1:3 in saline). After additional washes, the membranes were incubated with an anti-
rabbit IgG horseradish-peroxidase conjugate (1:5000, Goat anti-rabbit, Biorad) or anti-
monkey IgG (1:400, Gamonkey, Pierce- Rockford. IL, USA). Light emission was measured 
after the addition of the Western lightning chemiluminescence reagent (NLE 101, Perkin 
Elmer) using an ImageQuant RT ECL (General Electric Healthcare). 
Statistical analysis 
Samples were run in duplicate or triplicate. The results were expressed as the mean ± standard 
deviation. Comparisons between the two groups were analyzed by the nonparametric Mann–
Whitney test. The null hypothesis was rejected when P values were < 0.05. 
Results 
Intravenous delivery of rAAV5 under immunosupression is safe 
The IS regimen applied to the numbered and colour-coded macaques as described in Figure 
1A, maintained almost undetectable peripheral blood CD19
+
 B-lymphocytes for the duration 
of the protocol as an effect of Rituximab (Additional file 1: Figure 1A). The intensive IS 
regime reduced the absolute numbers of CD4
+
 and CD8
+
 T cells in peripheral blood 
(Additional file 1: Figure 1B-C) as a direct effect of ATG administration immediately before 
each rAAV infusion. Daily administration of MMF and FK506 for 12 weeks was used to 
functionally repress the remaining T and B lymphocytes. Studies by multicolour flow 
cytometry in peripheral blood indicate that the immunosuppressive drugs used did not 
selectively change the percentage of CD4
+
FOXP3
+
 regulatory T cells (Tregs) compared with 
effector T cells (data not shown). 
It is of note that the overall treatment did not cause worrying liver transaminase increases in 
serum and that blood counts including platelets were not altered in these non-human primates 
(Additional file 2: Figure 2). Moreover, upon rAAV vector administration there were only 
mild and transient increases in serum inflammation-denoting cytokines such as interleukin-6 
(Additional file 3: Figure 3). Accordingly, the IS regime does not seem to let AAV vectors to 
cause more serious inflammatory reactions. 
Immune responses to capsid antigens down-modulated by IS 
Direct intravenous injection of rAAV5 vector into a control naïve NHP001 macaque resulted 
in a robust antibody response (Figure 1B) and a moderate T-cell proliferative reaction against 
AAV5 capsid antigens (Figure 1C). The intensive IS regimen applied to NHP002 and 
NHP003 was able to restrain the humoral response (Figure 1B) and completely abolish the 
specific T cell responses to rAAV5 structural proteins as measured in a lymphocyte 
proliferation assay (Figure 1C). However, IS failed to attenuate the specific humoral response 
following withdrawal of the immunosuppressants and as a consequence the nAB titers rose 
about three-fold from the previously attenuated levels upon drug cessation (Figure 1B). 
Neutralizing antibodies detected in these macaques correlated with antibodies titers directed 
to adsorbed viral capsids in ELISA assays, that although showed lower sensitivity for 
detection, confirmed specificity (Additional file 4: Figure 4). Importantly, no antibodies 
directed against the human PBGD were detected by western blot assays at different time 
points through the study (Additional file 5: Figure 5). 
IS retards serum clearance of proviral DNA 
It was observed that under pharmacological immunosuppression circulating proviral DNA 
persisted for much longer periods of time than in the control NHP001 macaque, (with 
sustained proviral DNA levels up to fifteen weeks as detected by sequential QPCRs, as seen 
in Figure 1D). An in vitro transduction assay in PLC-PRF5 cells was performed with the 
serum from immunosuppressed animals at 2 and 7 weeks after rAAV5-pbgd administration. 
Lack of in vitro transduction of a sensitive cell line, as measured by specific QPCR in 
genomic DNA extracted from infected cells, suggested that the proviral DNA genomes in 
circulation did not represent infective viral particles. As a positive control for these 
experiments, rAAV5-pbgd vector readily caused productive transduction in parallel 
experiments at the same moi of 60 (data not shown). 
IS fails to allow for repeated gene transfer with AAV vectors of the same 
serotype 
To study if re-administrations of rAAV5 were feasible in animals with the aforementioned 
antibody titers (Figure 1B), a rAAV5 vector encoding the egfp reporter gene was given to the 
macaques 23 weeks later. None of the macaques pre-exposed to the pbgd-encoding rAAV5 
vector showed any liver expression of eGFP (Figure 2), while a control naïve macaque 
revealed measurable eGFP expression in the liver two weeks after vector administration 
(Figure 2A,B). 
Figure 2 Administration of second rAAV5 vector of the same serotype cannot achieve 
transgene expression even under immunosuppression of macaques with the five-drug 
regimen. A) Representative microphotographs of liver sections from the necropsy material of 
the indicated animals upon immunostaining with an anti-eGFP polyclonal antibody. The 
positive control animal (NHP004) received only a rAAV-egfp injection as indicated in Figure 
1. B) mRNA analysis by RT-PCR corresponding to specific egfp mRNA expression in liver 
of colour-coded animals. Data are expressed as median ± standard deviation of eight different 
lobes in each macaque. *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus naïve non-human 
primate 
Transgene expression persistence in an immunosuppressed macaque 
A second aim of our study was to analyze the ability of the transient IS regime to prolong 
transgene expression following the first injection of rAAV5-pbgd. Successful liver gene 
transfer following vector injection was confirmed by quantitative measurements of vector 
DNA in liver biopsies performed 15 days after the administration of the rAAV5-pbgd vector. 
To avoid “hit or miss” biopsy problems due to presumably non homogeneous expression of 
the transgene in the target organ, we took two needle biopsies from the right lobe and two 
more samples from the left lobe. No difference in vector genome copies in liver biopsies were 
observed between macaques with or without IS (data not shown). However, hepatic PBGD 
activity was not found to be increased in biopsies from any of the macaques during the first 
month after administration of rAAV5-pbgd (Figure 3A). Of interest, the liver of NHP002 
showed increased transgene expression as late as 25 weeks after vector administration, once 
having been free from IS for 13 weeks (Figure 3A). The macaque NHP003 which received 
the second vector administration again under IS did not show detectable increases in PBGD 
enzymatic activity (Figure 3B). These data were confirmed in liver samples taken upon 
necropsy at week 25 both at the mRNA level (Figure 3B) and upon immunohistochemical 
staining (Figure 3C). A possible interpretation to the detection of long-lasting transgene 
expression in NHP002 following IS cessation is that one or some of the IS agents could be 
interfering with transgene expression as conferred by rAAV5 vectors, although factors of 
individual variability could also be behind these results. The possibility of drug interference 
with gene expression was subsequently addressed in experiments performed in mice. 
Figure 3 Transient pharmacological immunosuppression fails to enhance rAAV5-
mediated gene transfer to the liver in macaques. A) Sequential follow-up of PBGD 
activity in homogenates from liver samples taken at the indicated time points. Normal range 
was defined as means ± 2 standard deviation of a separate group of four non-injected female 
macaques. B) Analyses of human pbgd mRNA content by quantitative RT-PCR in liver 
homogenates from necropsies taken at sacrifice (week 25). C) Immunohistochemistry 
detection of hepatocytes overexpressing PBGD on formalin-fixed and paraffin-embedded 
sections from liver biopsies obtained from the indicated animals at sacrifice. Data 
corresponding to necropsy samples (week 25) are expressed as median ± standard deviation of 
eight different lobes in each macaque 
MMF represses AAV-encoded transgene expression in the liver of mice 
Administration of MMF to groups of BALB/c mice transduced with rAAV5 encoding 
luciferase led to lower transgene expression in terms of photon emission upon 
bioluminescence analysis (Figure 4A). The addition of FK506 and Rituximab to the treatment 
regimen did not significantly further reduce transgene expression (Figure 4A), thus indicating 
that MMF was the main factor decreasing expression of the transgene. 
Figure 4 Mycophenolate mofetil (MMF) interference with transgene expression in mice. 
A) Sequential follow-up by bioluminescence of hepatic luciferase expression following an 
i.v. dose of 5x10
12
 genome copies of rAAV5-luciferase/kg in BALB/c mice with or without 
immunosuppressants at the indicated time points. B) The left graph represents luciferase 
expression measured as bioluminescence in the livers of Rag−/−, Rag−/−IL-2Rγ−/− and wild 
type syngeneic BALB/c mice 3 weeks after vector administration. The right graph shows 
proviral DNA content assessed by quantitative PCR in the liver of the same animals. C) The 
left graph represents sequential follow-up of hepatic luciferase expression following rAAV5-
luciferase/kg injection in BALB/c mice and Rag−/− mice. Four weeks following vector 
administration daily MMF was given for 15 days to the indicated groups. The right graph 
shows vector DNA quantification in the liver when mice were sacrificed three days after 
MMF cessation (45 days after vector infusion). ++, P < 0.01 versus wild type mice without 
immunosuppression 
MMF may have effects on target immune system cells as well as immune-independent off-
target effects. To ascertain whether the reduction of transgene expression was related to the 
existence of an adaptive immune system, we compared rAAV5 expression in wild type and 
Rag
−/−
 BALB/c mice, which are deficient in T and B lymphocytes. Expression of the 
luciferase transgene activity was approximately twice more intense in the wild type animals 
than in the Rag
−/−
 mice (Figure 4B left). Nonetheless, the amount of proviral DNA in the liver 
was similar, or even greater in immunodeficient than inmunocompetent mice (Figure 4B 
right), indicating that it is not a matter of liver gene transfer but of transgene expression. 
Similar data were observed with independently bred Rag
−/−
 IL-2Rγ−/− double knock-out mice 
that are also deficient in NK lymphocytes in addition to the lack of mature T and B cells 
(Figure 4B). 
To define if MMF was exerting its effects through the cellular immune system, we performed 
comparative experiments in Rag
−/−
 and wild type mice, with or without treatment with MMF. 
Importantly, MMF was administered four weeks after injection of our single stranded AAV5 
vector in order to avoid its interference effect on second-strand DNA synthesis [19,20]. MMF 
only decreased luciferase expression over baseline levels in the case of immunocompetent 
animals (Figure 4C left). Such a decrease in expression of luciferase despite similar levels of 
vector DNA (Figure 4C right), again indicates that MMF decreases transgene expression, but 
interestingly only when an adaptive immune system is present in the animal. 
Discussion 
Long lasting gene expression attained by rAAV-mediated gene transfer to the liver can be 
curative in a number of life-threatening metabolic diseases [2,4]. The genome of the rAAV 
vector persists predominantly in episomal forms, thereby increasing safety by reducing the 
risk of insertional mutagenesis. However, this feature may favour loss of genomes and 
transgene expression over time due to hepatocyte turn-over. Drug immunosuppressants create 
unresponsiveness to the viral capsid proteins and may provide a strategy to allow repetitive 
administration of the same vector. 
In our animals, intravenous delivery of rAAV5 activates significant humoral responses to 
AAV capsids but not to the cytosolic transgene product, which in the case of PBGD is an 
endogenously expressed protein that is highly conserved (99.2 % identity) between humans 
and macaca. Most probably, PBGD transgene protein will not elicit immune responses in a 
clinical trial for acute intermittent porphyria because the normal allele of PBGD produced in 
all cells from these patients should have induced immunological tolerance to the identical 
pbgd transgene-encoded protein. 
Notably, this is the first report performing rAAV administration under B-cell depleting 
treatment with rituximab. The humoral response against the AAV capsid was reduced in the 
two macaques during the three month period of intensive IS regimen when compared to the 
control macaque. Reduction was not complete denoting residual B cells and T-cell help for 
such a strong immunogen. Once the IS protocol was halted, the nAB levels reached the 
values obtained in the control macaque that did not receive IS. These data strongly indicate 
that upon IS cessation, the persistence of capsid antigens associated in some form with long-
lasting viral DNA permits a boost in the generation of anti-capsid antibodies. 
In previous work from other laboratories performed in rhesus macaques, in only one animal 
of the three treated daily with MMF and tacrolimus for 6 weeks did the levels of anti-AAV8 
IgG antibodies increase after IS therapy was stopped [12]. In another study, daily treatment 
with MMF and sirolimus for 10 weeks reduced humoral response against AAV2 capsid in 
rhesus macaques [10]. The anti-AAV2 nAB titer declined by week 13 and no rebound peak in 
the titer was observed following discontinuation of the IS regimen. These data suggest that 
the inclusion of rituximab in our regimen resulted in antigen persistence that becomes 
immunogenic following IS cessation. This can be interpreted in the sense that B cells and 
their production of antibodies are important for AAV antigen clearance. Hence, 
immunosuppressive regimens for AAV should permit clearance of vector antigens, while 
suppressing neutralizing humoral immunity. A recent report in mice suggests the use of non-
depleting anti-CD4 monoclonal antibodies combined with cyclosporine-A induced 
immunological tolerance mediated by regulatory T cells instead of immunosuppression [21]. 
Induction of antigen-specific tolerance to the AAV vector, as opposed to general 
immunosuppression, would be the best solution to a difficult problem and future research 
should focus on this matter. 
Data from a clinical trial of hemophilia B gene therapy with a rAAV2 vector [2,8,9] show 
that an increase in liver enzyme levels was associated with the generation of cytotoxic 
CD8 + T cell response specific for the rAAV2 capsid protein [9]. The finding that the 
cytotoxic T lymphocyte response eliminated gene expression in transduced cells was not 
observed in the clinical trial with rAAV8 trial where a course of glucocorticoid therapy was 
given [16]. It could be that the more rapid uncoating of rAAV8 than of rAAV2 capsid 
proteins from viral particles [22,23] allows the rAAV8 capsid proteins to be degraded by 
transduced cells before the immune system can seek and destroy them. Several studies have 
suggested that rate of uncoating of vector genomes is lower with rAAV2 than with serotypes 
rAAV5, rAAV6 and rAAV8 [18,23]. These results raise the possibility that serotypes 
different from rAAV2 behave less efficiently to develop T-cell mediated adaptive immune 
responses. 
In the present report, the control NHP showed a moderate T-cell proliferative reaction against 
AAV5 capsid antigens. This specific T cell response was completely abolished in the two 
animals that received immunosuppression. It is of interest that transgene expression was 
detectable six months after vector infusion in one of our macaques that received IS circa the 
first administration of vector. However, it had not been detectable in liver biopsies taken from 
the same animal two and four weeks after vector infusion while the animal was still under IS. 
This finding raises the issue of a potentially deleterious side effect of IS on transgene 
expression. Recent work [19] demonstrated that MMF inhibits the synthesis of the 
complementary DNA strand following entry of the rAAV into the target cells. In addition to 
this mechanism, we have experimentally documented in this study that MMF impairs 
transgene expression even when the transcriptionally active form of the provirus is already in 
place. The MMF effect required a functional adaptive immune system since this effect was 
not observed in Rag
−/−
 mice. Such an effect of MMF constitutes an unexpected result given 
that MMF is well studied as a repressor of immune functions. Paradoxical actions of MMF as 
a repressor of immune functions and in controlling hepatitis C virus (HCV) [24]and hepatitis 
B virus [25] have been reported in vitro. The mechanism of action on anti-HCV replication is 
still unknown but reported to be independent of cell proliferation and guanosine depletion 
[26]. 
Regardless of the mechanism, this pharmacological unexpected silencing effect of MMF is of 
particular relevance when considering the use of MMF to improve the outcome of rAAV-
mediated gene therapies. Our findings are in line with reference 24 and represent a warning 
for the design of future clinical trials. 
Conclusions 
IS controls the cellular immune response to AAV and one out of two macaques showed liver 
trangene expression 6 months after vector administration. However, our results indicate that 
rAAV5-liver mediated transgene expression in Macaca fascicularis poses immune-mediated 
obstacles that are unsatisfactorily overcome by the potent immunosuppressants used in 
combination. The reasons include: (i) incomplete restraint of humoral immune responses to 
viral capsids, (ii) an intriguing MMF-dependent drug-mediated interference with liver 
transgene expression that takes place via a so far elusive mechanism exerted with a 
requirement for a functional adaptive immune system. 
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Additional_file_1 as PPT 
Additional file 1: Figure S1. Follow-up of the absolute numbers of A) CD19
+
 B-
lymphocytes, B) CD4
+
 T-cells and C) CD8
+
 T-cells in the peripheral blood of the 
indicated colour-coded macaques measured by flow cytometry. Of note 
immunosuppressed animals on day 0 had already been treated with rituximab since day −9. 
Additional_file_2 as PPT 
Additional file 2: Figure S2. Follow-up of platelet counts, Aspartate Aminotransferase 
(AST) and Alanine Aminotransferase (ALT) in the sera from non-human primates after 
the second rAAV serotype 5 administration. 
Additional_file_3 as PPT 
Additional file 3: Figure S3. Serum interleukin-6 concentrations after A) the first and B) 
second AAV5 administrations to the indicated NHP. 
Additional_file_4 as PPT 
Additional file 4: Figure S4. Anti AAV5-capside antibody titer follows up by ELISA in 
sequential serum samples of the indicated macaques. 
Additional_file_5 as PPT 
Additional file 5: Figure S5. Lack of humoral response to the transgene protein 
Immunoblot analysis of hPBGD recombinant protein with serum from macaques 
injected with rAAV5-pbgd (1:3 dilution). An anti-PBGD specific polyclonal antibody was 
used as a positive control. 
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